Dilated cardiomyopathy screening

Dilated cardiomyopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Classification
Causes
Differentiating Dilated cardiomyopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Dilated cardiomyopathy screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dilated cardiomyopathy screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dilated cardiomyopathy screening
CDC on Dilated cardiomyopathy screening
Dilated cardiomyopathy screening in the news
Blogs on Dilated cardiomyopathy screening
Directions to Hospitals Treating Dilated cardiomyopathy
Risk calculators and risk factors for Dilated cardiomyopathy screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]

Overview

The current guidelines recommend screening for dilated cardiomyopathy in individuals with 2 or 3 family members with primary dilated cardiomyopathy. Screening can be performed using electrocardiograms and echocardiography to measure the size and function of the left ventricle. An underlying genetic mutation in the 40 genes (currently assessed in FCD genetic testing) can be detected in 30 to 40% of FCD patients.

Screening

Screening is only recommended in individuals who have a family history of Familial Dilated Cardiomyopathy (FDC).

• In case of 2 or 3 family members affected with primary DCM, reening of relatives, screenign of first degree relatives, using electrocardiogram and echocardiography allows the identification of FDC.
• FDC can be identified in 20–35% of DCM cases, while the remaining are classified as ‘idiopathic’
• FCD is primarily an autosomal dominant disease; however, cases with autosomal recessive or X-linked inheritance have been recognized.
• Genetic studies have revealed an underlying genetic mutation in 30 to 40% of patients with FCD.
• About 40 genes are currently included in genetic testing; however, mutations in >60 other genes have been linked to FCD, but are yet to be included.
• Recent guidelines from the Cardiac Genetic Diseases Council recommend genetic screening for family members at risk of developing FDC.
• A cohort study by Haas et al. showed that the genetic mutations in FCD overlap with other cardiomyopathies, highlighting the value of genetic testing in different types of cardiomyopathy.
• Current studies are focusing on the role of multiple mutations, enhancer region mutations, copy number variation, and intronic variants.